Anagenics Limited (ASX:AN1 – Get Free Report) insider Alexander (Sandy) Beard purchased 1,950,000 shares of the business’s stock in a transaction on Wednesday, May 7th. The shares were bought at an average cost of A$0.01 ($0.00) per share, for a total transaction of A$13,650.00 ($8,750.00).
Alexander (Sandy) Beard also recently made the following trade(s):
- On Monday, May 12th, Alexander (Sandy) Beard bought 226,876 shares of Anagenics stock. The stock was acquired at an average cost of A$0.01 ($0.00) per share, for a total transaction of A$1,361.26 ($872.60).
- On Thursday, May 8th, Alexander (Sandy) Beard bought 267,555 shares of Anagenics stock. The stock was acquired at an average cost of A$0.01 ($0.00) per share, for a total transaction of A$1,605.33 ($1,029.06).
- On Monday, May 5th, Alexander (Sandy) Beard bought 1,734,067 shares of Anagenics stock. The stock was acquired at an average cost of A$0.01 ($0.00) per share, for a total transaction of A$12,138.47 ($7,781.07).
Anagenics Price Performance
The company has a current ratio of 1.21, a quick ratio of 1.15 and a debt-to-equity ratio of 28.51. The company has a market cap of $3.69 million, a P/E ratio of -0.38 and a beta of -1.03.
About Anagenics
Anagenics Limited operates as a health and beauty tech company in Australia, New Zealand, and internationally. It develops and sells FGF5 inhibitor formulations; over-the-counter (OTC), cosmetic antiaging, and longevity targeting products; and imports and distributes international and local skin care and wellbeing products under the Thalgo, Hydro Peptide, Comfort Zone, Priori, and Inika Organic brand names.
Further Reading
- Five stocks we like better than Anagenics
- How to Calculate Inflation Rate
- Build a Complete Bond Portfolio With These 4 ETFs
- What Are Growth Stocks and Investing in Them
- MarketBeat Week in Review – 05/12 – 05/16
- Buy P&G Now, Before It Sets A New All-Time High
- Plug Power: Is Q1 Noise An Opportunity for Accumulation?
Receive News & Ratings for Anagenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anagenics and related companies with MarketBeat.com's FREE daily email newsletter.